Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving professional health literacy in hospitals: study protocol of a participatory codesign and implementation study.
Lubasch JS, Voigt-Barbarowicz M, Lippke S, De Wilde RL, Griesinger F, Lazovic D, Ocampo Villegas PC, Roeper J, Salzmann D, Seeber GH, Torres-de-la-Roche LA, Weyhe D, Ansmann L, Brütt AL. Lubasch JS, et al. Among authors: griesinger f. BMJ Open. 2021 Aug 16;11(8):e045835. doi: 10.1136/bmjopen-2020-045835. BMJ Open. 2021. PMID: 34400444 Free PMC article.
European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review.
Shah R, Girard N, Nagar SP, Griesinger F, Roeper J, Davis KL, Karimi P, Sawyer W, Yu N, Taylor A, Feliciano J. Shah R, et al. Among authors: griesinger f. Drugs Real World Outcomes. 2021 Dec;8(4):537-545. doi: 10.1007/s40801-021-00261-8. Epub 2021 Sep 17. Drugs Real World Outcomes. 2021. PMID: 34533784 Free PMC article.
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.
Roeper J, Falk M, Chalaris-Rißmann A, Lueers AC, Ramdani H, Wedeken K, Stropiep U, Diehl L, Tiemann M, Heukamp LC, Otto-Sobotka F, Griesinger F. Roeper J, et al. Among authors: griesinger f. Oncotarget. 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430. eCollection 2020 Jan 21. Oncotarget. 2020. PMID: 32076486 Free PMC article.
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: griesinger f. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
216 results